PRESS RELEASE

Biom’up strengthens management team

Saint-Priest, France, September 18, 2019 – 8h00 (CET) – Biom’up SA (the “Company”), specializing in surgical hemostasis, today announced that Patrice Ferrand was appointed CEO, replacing Dr. Jan Ohrstrom. Dr. Ohrstrom, who was appointed CEO in May of this year, remains Chairman of the Board, a role in which he…

READ

New Publication Highlights Application of HEMOBLAST™ Bellows in Cardiovascular Surgery

Article describes successful use and advantages of HEMOBLAST Bellows in high risk patients prone to bleeding undergoing cardiovascular surgical procedures. Saint-Priest, France, August 14th, 2019 – 8:00am (CET) – Biom’up (the « Company »), specializing in surgical hemostasis, today announced the publication of clinical case studies highlighting the use of the Company’s…

READ

Biom’up provides business update for the first half of 2019 and confirms its revenue guidance for the year

Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal • Operating expenditures for 2019 expected to…

READ

Biom’up provides 2019 guidance for HEMOBLAST™ Bellows global sales

Saint-Priest, France, May 20, 2019 – 8h00 (CET) – Biom’up (the « Company »), specializing in surgical hemostasis, is providing for the first time, full-year 2019 guidance for global sales of HEMOBLAST Bellows (including its laparoscopic applicator) in the range of €4.0-4.5 million. Biom’up provides full-year 2019 guidance for global sales of…

READ

Biom’up announces first US sales in laparoscopy for HEMOBLAST™ Bellows and the signing of an exclusive distribution agreement for HEMOBLAST™ Bellows in Australia

Saint-Priest, France, April 15th, 2019 – 8h00 (CET) – Biom’up SA (the “Company »), specializing in surgical hemostasis, announces today first sales on the US market of its HEMOBLAST Bellows Laparoscopic Applicator. Successful launch of the HEMOBLAST Bellows Laparoscopic Applicator in the US, first sales booked in March 2019 Major framework…

READ

Biom’up appoints George Makhoul as Chief Commercial Officer (USA)

Saint-Priest, France, January 31, 2019 – 8h00 (CET) – Biom’up (the « Company »), specializing in surgical hemostasis, today announced the appointment of George Makhoul as Chief Commercial Officer with responsibility for the United States, effective today. Mr. Makhoul has a track record in commercializing medical products to hospitals and surgeons combined…

READ

Biom’up HEMOBLAST™ Bellows full pivotal trial results published in Journal of Cardiac Surgery

Saint-Priest, France, January 30, 2019, 8:00 am (CET) – Biom’up (the “Company”), a specialist in surgical hemostasis, today announced the publication of scientific and clinical data with the Company’s lead product HEMOBLAST Bellows, a hemostatic product to control bleeding in a broad range of both traditional and laparoscopic surgical procedures…

READ

Biom’up granted FDA approval for its HEMOBLAST™ Bellows Laparoscopic Applicator

Saint-Priest, France, January 22, 2019, 8:00 am (CET) – Biom’up (the “Company”), specializing in surgical hemostasis, has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its HEMOBLAST Bellows Laparoscopic Applicator for all minimally-invasive procedures. Biom’up submitted the premarket approval (PMA) supplement to the FDA…

READ

Achievement of two major development milestones

Saint-Priest, France, January 7, 2019, 8:00 am (CET) – Biom’up (the “Company”), a specialist in surgical hemostasis, today announces an IDE (Investigational Device Exemption) application submitted to the FDA for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate for managing minimal and mild levels of bleeding…

READ

Biom’up sees a strong commercial uptake in HEMOBLAST™ Bellows in the US and Europe

Saint-Priest (France), November 28, 2018, 8:00 am (Paris time) – Biom’up (the “Company”), a specialist in surgical hemostasis, announces today an update on its first months of commercialization of HEMOBLAST Bellows in the US and Europe and confirms a strong uptake among hospitals and surgeons. HEMOBLAST Bellows now used in…

READ

Caution: Federal law restricts this device to sale on or by the order of a physician. The trademark of HEMOBLAST™ Bellows and SPOT GRADE™ are the property of Biom’up. The trademarks of the products listed herein are trademarks of their respective manufacturer. Please refer to the Instructions for Use accompanying each device for further information. The presentation contains pictures owned by third party and remains their property.
E-MR-318-V1
HEMOBLAST™ Bellows Hemostatic Agent [instructions for use: E-MR-217-V6]